SUPN News & Events

Jefferies analyst Andrew Tsai notes that the highest level of the U.S. government has signed an executive order to encourage the DEA to reschedule medical marijuana to a less stringent CIII for CNS indications like pain. The firm could see non-recreational psychedelics eventually follow suit, as long as sponsors continue producing Phase II/III data to suggest psychedelics can safely produce profound efficacy in mental health - arguably a function of time. Jefferies notes it thinks Atai Beckley's (ATAI) proprietary psychedelics have promise in tough $1B-plus mental health disorders. Other publicly traded companies in the space include Supernus (SUPN) and Cybin (CYBN).

Consensus $702.59M. Raises FY25 adjusted operating earnings view to $125M-$145M from $105M-$135M. The company said, "The Company is updating its full year 2025 financial guidance primarily to reflect strong performance in the first nine months of 2025."